Patheon Signs Flexible Manufacturing Agreement with Amgen
News Apr 28, 2016
Patheon has announced that it has signed a manufacturing agreement with Amgen. Amgen has selected Patheon to provide flexible manufacturing solutions to meet the growing demand for their innovative human therapeutics. “As we launch new products and expand into more countries, it is critical to have the capacity to respond to increases in demand for our medicines,” said Rayne Waller, vice president, global supply chain at Amgen.
“Manufacturing remains a core competency and a competitive advantage for Amgen and we are committed to supplying every patient, every time. This arrangement with Patheon supplements our own manufacturing network and provides us flexibility to ensure supply.” The rapidly changing biopharmaceutical marketplace presents tremendous challenges for biotechnology companies when it comes to demand forecasting.
To address this, Patheon has developed unique solutions and business models providing flexible manufacturing options for clients to address the complex client needs in a changing landscape. “We believe the departure from the “build or buy” paradigm represents a superior value for our clients,” said Michael Lehmann, executive vice president, global sales and marketing for Patheon.
“These flexible capacity solutions require a strategic and collaborative approach – different from the traditional “price per batch” concept. This agreement with Amgen is representative of the changing dialogue in the pharmaceutical services industry.” Patheon provides world class process development and cGMP manufacturing services for both drug substance and drug product, from pre-clinical to commercial supply, to its global client base.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018